Future trends in human brucellosis treatment.

Area of Science:

• Infectious Diseases
• Bacteriology
• Immunology

Background:

• Human brucellosis presents a significant global health challenge.
• Current treatments for brucellosis are based on outdated protocols and are not optimal.
• Understanding brucellosis pathophysiology is key to developing superior therapeutic strategies.

Purpose of the Study:

• To review and evaluate current and potential future approaches for treating human brucellosis.
• To assess the cost-effectiveness of alternative treatment regimens.
• To explore novel therapeutic strategies and vaccine development for brucellosis.

Main Methods:

• Review of existing literature on brucellosis treatment and vaccine development.
• Evaluation of alternative treatment regimens, including co-trimoxazole and novel antibiotics like tigecycline.
• Consideration of advanced delivery systems such as gentamicin-loaded microparticles.
• Assessment of immunomodulation's role in brucellosis management.
• Analysis of challenges and requirements for developing a subcellular vaccine.

Main Results:

• Existing brucellosis treatments are adequate but suboptimal.
• Co-trimoxazole-containing regimens show promise for cost-effective treatment.
• Novel approaches like gentamicin microparticles, environmental neutralization, and tigecycline warrant future investigation.
• The role of immunomodulation requires further evaluation across all disease stages.
• Development of a trivalent subcellular vaccine is proposed as a necessary step for efficacy, despite technical and financial hurdles.

Conclusions:

• Optimizing human brucellosis treatment requires exploring alternative and novel therapeutic strategies.
• Cost-effective regimens and advanced drug delivery systems are crucial for future management.
• A comprehensive approach including immunomodulation and a specifically designed subcellular vaccine is needed to effectively combat brucellosis.